Brain-derived neurotrophic factor (BDNF) is neuroprotective in the ischemic
hippocampus if the neurotrophin is injected directly into the brain. Howev
er, the efficacy of BDNF via peripheral (i.v.) administration is limited by
the lack of transport of the neurotrophin through the brain capillary wall
, which makes up the blood-brain barrier (BBB) in vivo. The present studies
describe a molecular reformulation of BDNF that incorporates polyethylene
glycol (PEG) moieties at surface carboxyl residues, to optimize plasma phar
macokinetics, and links pegylated BDNF to the OX26 mAb, which undergoes rec
eptor-mediated transport through the BBB via the brain capillary endothelia
l transferrin receptor. The BDNF-PEG 2000-biotin conjugated to OX26/strepta
vidin was administered i.v. daily to rats for 1 week after a 12-min period
of transient forebrain ischemia. The neuronal density in the CA1 sector of
the hippocampus was decreased 68 +/- 10% at 1 week after the ischemia. Ther
e was no neuroprotective effect of the unconjugated BDNF or unconjugated OX
26 mAb. However, the hippocampal CA1 neuronal density was normalized by i.v
. administration of the BDNF-PEG 2000-biotin conjugated to OX26/streptavidi
n. These studies demonstrate that peripherally administered BDNF may have n
europrotective effects in brain, if the neurotrophin is reformulated to (i)
optimize plasma pharmacokinetics with carboxyl-directed pegylation, and (i
i) enable transport through the BBB by coupling to brain transport vectors.